Springfield Clinic

Running trials

• Recruiting

  Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

  NCT06948084· Phase 2· Source

• Recruiting

  Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

  NCT07578116· Phase 3· Source

• Recruiting

  Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  NCT07388524· Phase 3· Source

• Recruiting

  Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· Phase 2· Source

• Recruiting

  Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT07393555· Phase 2· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· Source

• Recruiting

  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

  NCT07220187· Phase 3· Source

• Recruiting

  Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

  NCT06998940· Phase 3· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Source

• Recruiting

  Family Communications After Genetic Testing

  NCT07143487· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

  NCT07440225· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  NCT07283939· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· Source

• Recruiting

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· Phase 3· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· Source

• Recruiting

  Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

  NCT07018869· Phase 3· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· Source

• Active, not recruiting

  Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

  NCT06732401· Phase 3· Source

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Source

• Recruiting

  Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT07064759· Phase 3· Source

• Recruiting

  Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  NCT06577441· Phase 2· Source

• Recruiting

  High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  NCT06992427· Phase 3· Source

• Recruiting

  Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  NCT06770582· Phase 2· Source

• Recruiting

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· Phase 2/3· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· Phase 3· Source

• Recruiting

  A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  NCT06581328· Phase 4· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· Source

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Source

• Recruiting

  Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

  NCT06470243· Phase 3· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  NCT06116682· Phase 2· Source

• Recruiting

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· Phase 3· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· Source

• Recruiting

  Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  NCT06422806· Phase 3· Source

• Active, not recruiting

  A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

  NCT06566716· Source

• Active, not recruiting

  The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

  NCT06115499· Phase 2/3· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  NCT06031688· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Colorectal cancer11 recruiting
• Bladder cancer9 recruiting
• Ovarian cancer7 recruiting
• Pancreatic cancer7 recruiting
• Acute myeloid leukemia6 recruiting
• Childhood cancers6 recruiting
• Head and neck cancer6 recruiting
• Gastric and esophageal cancer5 recruiting
• Kidney cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Multiple myeloma5 recruiting
• Prostate cancer5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Melanoma4 recruiting
• Myelodysplastic syndromes3 recruiting
• Cervical cancer2 recruiting
• Endometrial cancer2 recruiting
• Macular degeneration2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroendocrine tumours2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Diabetic eye disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Mantle cell lymphoma1 recruiting
• Sarcoma1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Source

• Terminated

  Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

  NCT04936230· Phase 2· Source

• Terminated

  Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

  NCT04871529· Phase 2· Source

• Withdrawn

  Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

  NCT05364645· Phase 2· Source

• Completed

  Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

  NCT03941860· Phase 3· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Source

• Completed

  Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

  NCT04600336· Phase 2· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· Source

• Completed

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· Phase 2· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Source

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· Source

• Completed

  Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

  NCT03963739· Source

• Completed

  Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

  NCT03707574· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· Source

• Completed

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· Phase 2· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· Source

• Completed

  Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

  NCT03633331· Phase 2· Source

• Completed

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· Phase 2· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· Source

• Completed

  Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· Source

• Completed

  Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT02844816· Phase 2· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Source

• Completed

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· Phase 2· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· Source

• Completed

  Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390· Phase 2· Source

• Completed

  S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

  NCT01959139· Phase 1/2· Source

• Completed

  Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01708941· Phase 2· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· Source

• Completed

  S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

  NCT01668719· Phase 1/2· Source

• Completed

  Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

  NCT01286272· Phase 2· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Source